title: Comment on 'anti-adhesion therapies and the rule of 3 for rare events'.
authors.affiliation: Robarts Clinical Trials Inc., London, Ontario, Canada.
authors.forename: Brian G
authors.initials: BG
authors.lastname: Feagan
authors.affiliation: Icahn School of Medicine at Mount Sinai, New York, New York, USA.
authors.forename: Jean-Frederic
authors.initials: JF
authors.lastname: Colombel
authors.affiliation: Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
authors.forename: Stephen B
authors.initials: SB
authors.lastname: Hanauer
authors.affiliation: Takeda Pharmaceuticals Inc., Deerfield, Illinois, USA.
authors.forename: Asit
authors.initials: A
authors.lastname: Parikh
authors.affiliation: University Hospitals Leuven, Leuven, Belgium.
authors.forename: Paul
authors.initials: P
authors.lastname: Rutgeerts
authors.affiliation: University of San Diego California, La Jolla, California, USA.
authors.forename: William J
authors.initials: WJ
authors.lastname: Sandborn
authors.affiliation: Icahn School of Medicine at Mount Sinai, New York, New York, USA.
authors.forename: Bruce E
authors.initials: BE
authors.lastname: Sands
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D002464:Cell Migration Inhibition / Q000187:drug effects*; D003424:Crohn Disease / Q000188:drug therapy*; D006801:Humans; D007968:Leukoencephalopathy, Progressive Multifocal / Q000139:chemically induced*
chemical_list: D061067:Antibodies, Monoclonal, Humanized